Clinical Trial Update: Rituxmab Versus IL-6 in Treating ILD [Phase 2, Phase 3]

View source ↗

Summary

Phase 2/3 trial comparing Rituxmab to IL-6 in treating Interstitial Lung Disease and scleroderma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Interstitial Lung Disease
• Systemic Sclerosis

Drugs mentioned

• IL-6 (interleukin-6)
• Rituxmab (rituximab)

Snippet

Sponsor: Assiut University | Conditions: Interstitial Lung Disease, Scleroderma | Phase 2, Phase 3 | Status: COMPLETED